E

Enliven Therapeutics
D

ELVN

57.490
USD
-1.91
(-3.22%)
Post Trading·57.660USD+0.170(+0.30%)
حجم التداول
0
الربح لكل سهم
-0
العائد الربحي
-
P/E
-35
حجم السوق
4,212,336,050
المقالات
المزيد

العنوان: Enliven Therapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.